5 Best Low Priced Stocks to Get Rich in 2026

2. Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Upside Potential as of June 18, 2026: 195.92%

Number of Hedge Fund Holders: 37

On June 12, BofA started coverage on Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a Buy rating and a price target of $35. According to the firm, the company is a “cleaner, single-asset immunology story” following the positive Phase 2 data in hidradenitis suppurativa. If the company’s lead product, abdakibart, is compared with alternative drugs, the former may provide a more convenient monthly dosing schedule and greater impact on disease outcomes, the firm added.

BofA views the investment case as “a differentiated IL-1β antibody in HS, a large undertreated market, and a balance sheet with runway through next major data readout into 2029e after ~$405M net proceeds.”

The company’s one-year return is what catches the eye, with an impressive 183% market outperformance. This doesn’t stop here as the company’s future looks equally promising. With a bullish stance from all 14 analysts covering the stock, Avalo Therapeutics, Inc. (NASDAQ:AVTX) has a 1-year upside potential of 195.92%. No wonder AVTX is among the best low-priced stocks to get rich in 2026.

Avalo Therapeutics, Inc. (NASDAQ:AVTX), incorporated in 2011, is a Pennsylvania-based clinical-stage biotechnology company that provides solutions for immune-mediated inflammatory diseases. The company’s lead candidate is AVTX-009.

1281292 - 11759070 - 1